Pentixather

Herrmann K, Schottelius M, Lapa C, Osl T, Poschenrieder A, Hänscheid H, Lückerath K, Schreder M, Bluemel C, Knott M, Keller U, Schirbel A, Samnick S, Lassmann M, Kropf S, Buck AK, Einsele H, Wester HJ, Knop S.

J Nucl Med. 2016 Feb;57(2):248-51.

doi: 10.2967/jnumed.115.167361.

First-in-Human Experience of CXCR4-Directed Endoradiotherapy with 177Lu- and 90Y-Labeled Pentixather in MM.

CONCLUSION:

CXCR4-targeted radiotherapy with pentixather appears to be a promising novel treatment option in combination with cytotoxic chemotherapy and autologous stem cell transplantation, especially for patients with advanced multiple myeloma.

Schottelius M, Osl T, Poschenrieder A, Hoffmann F, Beykan S, Hänscheid H, Schirbel A, Buck AK, Kropf S, Schwaiger M, Keller U, Lassmann M, Wester HJ.

Theranostics. 2017, in press

in press

[177Lu]pentixather: comprehensive preclinical characterization of a first CXCR4-directed endoradiotherapeutic agent.

No abstract available.

Constantin Lapa, Ken Herrmann, Heribert Hänscheid, Katharina Lückerath, Margret Schottelius, Malte Kircher, Rudolf A. Werner, Martin Schreder, Andreas Schirbel, Samuel Samnick, Saskia Kropf, Stefan Knop, Andreas K. Buck, Hermann Einsele, Hans-Juergen Wester, and K. Martin Kortüm

Theranostics. 2017, in press.

in press

CXCR4-directed endoradiotherapy induces high response rates in extramedullary relapsed Multiple Myeloma.

No abstract available